Index to Volume Twenty-eight

Index of Issues: January, 1–62; February, 63–124; March, 125–186; April, 187–246; May, 247–308; June, 309–362; July, 363–430; August, 431–492; September, 493–554; October, 555–612; November, 613–680; December, 681–738.

INDEX OF AUTHORS

A

Abdellati S, 539
Achilles SL, 417
Ackers ML, 166
Adimora AA, 69
Adler N, 533
Agacfidan A, 630
Aguilar L, 47
Agüanell MV, 47
Alary M, 437
Alcala B, 576
Allister L, 143
Alp T, 630
Alter MJ, 4
Alves MC, 710
Amca B, 58
Amortegui A, 240
Anderson LA, 336
Ang O, 630
Antinori A, 298, 405
Aral SO, 69
Aramburu J, 11
Areal KR, 710
Aronson KJ, 694
Artz L, 387
Ashley RL, 99, 187
Aubin MR, 287
Augenbraun M, 143, 158
Aydin D, 58, 630

B

Badur S, 630
Bakary DK, 690
Ballesteros J, 47
Bandeira MGC, 521
Bass DC, 240
Baumgartner T, 136
Beltrame A, 343
Benas DM, 349
Benešova V, 356
Benvenuti M, 298
Benzaken AS, 521
Bergeron MG, 484
Berglund T, 111
Bergman N, 259
Bernier F, 437
Biro FM, 527
Bittner H, 321
Black C, 4
Blackhouse G, 701
Blair R, 232
Boceta R, 47
Boeke AJP, 496
Boekeloo BO, 477
Boerma JT, 214
Boily M-C, 437
Bolan G, 117, 535
Borsboom GJJM, 633
Bosch FX, 187
Boslego JW, 555
Bouter LM, 496
Boyer CB, 349
Brady AR, 379
Brady W, 158
Brandstetter DM, 43
Braxton J, 497
Brewer DD, 666
Brodine SK, 349
Brody S, 730
Bromberg K, 412
Brown DR, 226
Brown JE, 608
Buchbinder S, 51
Bugarini R, 690
Bullard J, 4
Burkham S, 315
Burstein GR, 477
Bwayo J, 394, 633

C

Cabral R, 387
Caceres CF, 11
Calcaterra S, 298
Caldwell MB, 315
California Coalition of Local AIDS Directors, 460
California STD Controllers Association, 460
Cameron DW, 579
Campbell J, 565
Carbonneau D, 437
Caribbean GASP Network, 508
Carlson R, 171
Carosi G, 343
Casalini C, 343
Castellano T, 11
Catalani C, 298
Catchpole MA, 379
Cates W Jr, 552
Celum CL, 99, 219
Cent A, 99
Chandeying V, 648
Chernesky M, 701
Chery F, 412
Chong S, 701
Ciravolo G, 343
Claeys G, 372
Claeys P, 372
Clark A, 219, 565, 658
Cles L, 219
Cobb BK, 236, 444
Conde-Glez CJ, 125, 270
Cone RA, 417
Conley D, 477
Cook DA, 424
Coppola N, 725
Corey L, 176
Cosgrove-Sweeney YT, 363
Cotton S, 527
Covino JM, 569
Crawford D, 11
Critchlow C, 51
Cromwell PF, 43
Crosby R, 208, 236, 444, 468
Crouse K, 565
Cruz A, 270
Curtis R, 598

D

Dal-ré R, 47
Davies SL, 208, 236, 444
Dawar M, 424
Deal CD, 555
Deguchi T, 472
Dehovitz J, 624
Deliopolu J, 356
Des Jarlais DC, 598
Désormeaux A, 484
Devillé W, 496
de Vlas SJ, 613
Diamond C, 176
Di Carlo A, 298
DiClemente RJ, 208, 236, 444, 468, 515
Dieterich-Colón S, 401
Dillon J-AR, 508, 521
Dirk VH, 539
Diseker RA III, 330
Dixon J, 336
Doherty-Iddings P, 51
Dohnal K, 356
Dominguez KL, 315
Donaldson KH, 69
Douglas JM Jr, 136, 226, 330, 535
Dowe G, 266
Dragsted DM, 326

E

Eldred SL, 455
Ellen JM, 533
Eluf-Neto J, 187
Enbom M, 300
Eng SM, 77
Erbelding EJ, 281
Eschenbach DA, 569

F

Falck R, 171
Falk KI, 300
Farholt S, 326
Farley TA, 117, 497
Faxelid E, 105
Feldblum PJ, 655
Feldman J, 624
Feldman SR, 643
Fenton KA, 379
Ferenczy A, 226, 694
Fernández-Verdugo A, 115
Fichtner RR, 92
Fife KH, 226
Filho EDSF, 521
Filippini P, 725
Finelli L, 40, 131
Fiorito SM, 29
Fishbein M, 535
Fleischer AB Jr, 643
Flom PL, 598
Fonck K, 367, 372
Fontanet AL, 648
Forleo MA, 343
Fortenberry JD, 117, 247
Foy A, 701
Franco EL, 694
Fredlund H, 111
Friedman HB, 714
Friedman SR, 598
Fullilove RE, 69

G

Gagné N, 484
Galarza PG, 29
Garbuglia AR, 298
García-Cisneros S, 125
García-Corbeira P, 47
Garnett GP, 579, 622
Garrett SB, 666
Gattari P, 405
Gaydos CA, 356
Gefter LR, 43
Gerbase AC, 710
Gibson JJ, 497
Giesecke J, 111
Gift TL, 714
Giuliani M, 298
Glenn R, 643
Glikoutou M, 690
Goeree R, 701
Golden MR, 658
Gorbach PM, 658
Gotuzzo D, 11
Gourde P, 484
Gowda VR, 336
Goyzueta G, 11
Graifemberghi S, 343
Grant AR, 608
Grant EMJ, 608
Gray RH, 77
Grey SF, 401
Griffiss JM, 555
Grivna M, 356
Gross M, 51
Gulletta M, 343
Gunn RA, 166, 455
Gutiérrez Y, 82
Guzmán D, 82

H

Habbema JDF, 613, 633
Haikala O, 252
Hamaker D, 315
Hamel MJ, 153
Handsfield HH, 117, 219, 464, 658
Hardison WGM, 166
Harezlak J, 247
Harrington K, 208, 236, 444, 468
Hatzell T, 655
Healey SM, 694
Hegarty TA, 417
Heine RP, 321
Hendrix SL, 240
Hergenrather KC, 515
Hermida T, 401
Hernández-Avila M, 125, 277
Hernández M, 270
Herrero R, 187, 277
Higa H, 309
Hillier SL, 240, 363, 569
Hillis SE, 117
Hiltunen-Back E, 252
Hoen TE, 417
Hogan T, 281
Höjer B, 105
Holley RL, 240
Holman S, 624
Holmes KK, 658

Hook EW III, 11, 136, 208, 236, 444, 448, 468
Horák J, 356
Horth F, 546
HPV Study Group, 226
Hughes G, 379
Hughes JP, 658
Hummel B, 281
Hutcheson D, 315
Hwong H, 184

I
Iatesta M, 330, 535
Ippolito G, 298, 405
Irwin K, 232
Irwin KL, 336
Ishiko H, 472
Isik N, 630
Ismailov R, 372
Ito SI, 349

J
Jabbarova A, 372
Jang D, 701
Jerse AE, 417
Jiang B, 171
Jivasak-Apimas S, 648
Joesoef MR, 158
Johnson R, 158
Jolly A, 14, 200
Joly JR, 437
Jones R, 136
Juárez-Figueroa L, 270
Juárez-Figueroa LA, 125
Judson FN, 51, 153

K
Kacena KA, 356
Kamb ML, 330, 535
Kambugu F, 105
Kapernick P, 569
Karita E, 539
Kartchner D, 565
Katz BP, 247
Kautiainen H, 252
Kee R, 678
Kelen GD, 33
Kellinger K, 321
Kendrick JS, 292
Kent C, 117, 330
Kilmarx PH, 347
Kinghorn GR, 379
Kiriwat O, 648
Kirui P, 367
Kissinger P, 117
Kiwanuka N, 77
Klausner JD, 464
Klovdahl AS, 25
Knapp JS, 309
Kojima K, 472
Korenromp EL, 613
Kottiri BJ, 598
Koumans EH, 292, 497
Krajden M, 424
Kreider JW, 417
Kreiss JK, 394
Krekeler B, 219
Krohn MA, 321
Kuo C-C, 493
Kuperus AG, 633

L
Lafort Y, 539
Laga M, 539
Langley C, 497
Lavreys L, 394
Lawing LF, 195
Lawlor J, 448
Lawrence JM, 535
Lazcano-Ponce E, 270, 277
Lazebnik R, 401
Lentz A, 330
Leone P, 136
Levine WC, 131, 315, 347
Leyva A, 277
Li C, 77
Li H, 508, 521
Linde A, 300
Lind I, 326
Lindstrom JA, 555
Lin LS, 330
Litchfield B, 117
Llanes R, 82
Llop A, 82
Lowry DLB, 321

M
Macaluso M, 387
MacKellar D, 176
Maeda S-I, 472
Maguire RA, 259
Maharry K, 678
Mahe C, 431
Mahoney F, 148
Mahony J, 701
Malinski C, 658
Malotte KC, 330
Mandaliya K, 394
Mao Y, 694
Marcellino L, 412
Margolis H, 148, 166
Markowitz LE, 287
Marmor M, 51
Marrazzo JM, 219
Martin DH, 136
Martin HL Jr, 394
Martinson FEA, 69
Mast E, 148
Mathews C, 455
Matteelli A, 343
Mayanja B, 431
Mayer KH, 464
McClain JB, 555
McCormack WM, 136, 569
McFarlane M, 497
McGregor J, 569
Mehta S, 412
Mehta SD, 33
Meijer CJLM, 277, 496
Mercey DE, 379
Mery LS, 694
Micheni KD, 608
Miguel MD, 576
Mills L, 527
Miranda AE, 710
Mock PA, 347
Moench TR, 417
Moncada J, 630
Morgan D, 431
Morré SA, 496
Morris M, 504
Mottice S, 565
Mou S, 569
Moyer L, 148
Mroczkowski TF, 136
Muñoz N, 187, 270, 277
Murray PJ, 166
Muthiri FM, 608
Mwai C, 367
Mwenda JM, 608

N
Nagelkerke NJD, 613
Nathan L, 92
Ndinya-Achola J, 367, 394, 633
Neaigus A, 598
Neal SW, 309
Ness RB, 240
Neto RL, 710
Ngabonziza M, 539
Ngelangel C, 187
Ng HC, 424
Ngugi E, 394
Nnko S, 214
Noell J, 4
Nsubuga PSJ, 105
Nuwaha F, 105

O
Ochs L, 4
O'Donnell JA, 158
O'Farrell N, 84
O'Hara HB, 633
Oh MK, 117, 208, 236, 444, 468
Okongo JM, 431
Olmsted SS, 417
Omar RF, 484
Onel M, 630
Onofrio M, 725
Orr DP, 247
Ortayli N, 58
Otero L, 576
Otido JM, 633
Oviedo CI, 29
Owens ML, 226

P
Paavonen J, 252
Paffel JM, 315
Pagano EI, 29
Paris M, 11
Parrish CA, 643
Patrick DM, 424
Patton DL, 363
Peipert J, 240
Perdue T, 176
Pérez F, 115
Pérez S, 115
Perkins SM, 678
Perron S, 484
Person S, 468
Peterman T, 330, 535
Pettit D, 565
Phillips DM, 259
Piccinino F, 725
Piret J, 484
Platt R, 232
Poindexter AN III, 546
Posner SF, 387
Potterat JJ, 730
Poulin C, 437
Prabhakar P, 508
Pulley LV, 387

Q
Quinn TC, 33, 356, 448, 477

R
Rabe LK, 363
Radolf JD, 158
Rakwar J, 367
Randall H, 240
Ratelle S, 232
Rathe S, 372
Rawstron SA, 412
Rein DB, 336
Rein MF, 569
Rekart ML, 424
Rempel J, 412
Reunala T, 252
Rezza G, 298, 405, 690
Rhodes F, 330, 535
Rhodes SD, 515
Ricardo O, 82
Richardson BA, 394
Ridgway GL, 2
Rietmeijer CA, 153
Risser JMH, 43
Risser WL, 43
Rochat RW, 92
Rogers PA, 379
Rohde P, 4
Rojanapithayakorn W, 648
Rolfs RT, 158
Rompalo AM, 158, 448
Rosen T, 184
Rosenthal SL, 527
Rossi G, 725
Ross MW, 497
Rothenberg R, 63
Rothman RE, 33
Røttingen J-A, 579
Rubabaza J-PA, 521
Ruben M, 508
Rugpao S, 648

S
Saba J, 648
Sagnelli E, 725
Sahip N, 58
Sahip Y, 58
Sakondhavat C, 648
Salmerón J, 277
Sandoval M, 598
Sandul AL, 309
Sangi-Haghpeykar H, 546
Sardinha JCG, 521
Sarmati L, 690
Say L, 58
Schachter J, 349, 495
Schillinger JA, 40, 287
Schlecht NF, 694
Schmid G, 148
Schmid S, 4
Schmidt KA, 555
Schneider H, 555
Schoenbach VJ, 69
Schulte JM, 315
Schwebke JR, 195
Scolastico C, 725
Scotti R, 51
Sealy J, 508
Seaman P, 448
Seattle & King County Public Health, 457
Seattle Young Men's Survey Team, 176
Sellors J, 701
Serwadda D., 77

Sewankambo NK, 77
Shafer M-AB, 349
Shaffer RA, 349
Shah KV, 62
Shultz M, 321
Siegal H, 171
Sionéan C, 208, 236, 444
Smikle MF, 266
Smith JS, 187, 270
Smith M, 226
Snyder MH, 477
Sondheimer SJ, 240
Soper DE, 240
Sosa J, 82
Sparo M, 29
Spielberg F, 51
Spieler J, 552
Spizzichino L, 405
St. Louis ME, 117, 131, 287, 315, 497
Stamm WE, 219, 684
Steece R, 565
Stevens CE, 394
Stoll BJ, 92
Stoner BP, 136
Strand A, 300
Succop PA, 527
Suligoi B, 690
Susanti I, 714
Sweet RL, 240, 321
Szubski R, 401

T

Tamaki M, 472
Tang Y, 232
Tao G, 232
Tchamgmena O, 690
Tedoldi S, 343
Temmerman M, 367, 372
Thesiger C, 266
Thiede H, 176
Thin RN, 379
Thomason JL, 569
Toma L, 690
Toomey KE, 92
Trızna R, 356
Trees DL, 309
Tremblay MJ, 484
Trucco G, 240
Tu W, 247

U

Urassa M, 214
Uribe-Salas FJ, 125
Uusküla A, 624

V

Valentine J, 131
Valleroy LA, 176
van den Brule AJC, 496
Van de Verg L, 555
Van Dyck E, 539
van Valkengoed IGM, 496
Varela JA, 47, 576
Vazquez F, 115, 576
Vazquez JA, 576
Vázquez-Valdés F, 47
Vermund SH, 11
Vittinghoff E, 51
Voeten HACM, 633
Voigt R, 148
Von Ranson KM, 527

W

Walboomers JMM, 277
Wang J, 171
Warner L, 92
Warren RA, 555
Washija R, 214
Wasserheit JN, 40, 714
Wawer MJ, 77
Whaley KJ, 417
Wheeler CM, 125
Whelan M, 232
Whittington WLH, 99, 117, 219, 658
Whitworth JAG, 431
Wiesenfeld HC, 321
Williams EM, 266
Wilson BC, 148
Wilson TE, 143, 285, 624
Wingood GM, 208, 236, 444, 468
Winston Y, 678
Wylie JL, 14, 200

X

Xu F, 287

Y

Yang J, 136
Yasuda M, 472
Yee LJ, 515
Yniguez DL, 349
Yokoe D, 232
Yoshida T, 472
Yovanoff P, 4

Z

Zaccarelli M, 298, 405
Zamilpa-Mejía LG, 125
Zanto S, 565
Zeitlin L, 417
Zenilman J, 33, 281, 330, 448, 477, 535, 598
Zimet GD, 678

STATEMENT OF OWNERSHIP MANAGEMENT AND CIRCULATION (Required by 39 U.S.C. 3685) 1. Publication Title: SEXUALLY TRANSMITTED DISEASES 2. Publication no.: 0148–5717 3. Filing date: 10–01–01. 4. Frequency of issue: Monthly 5. No. of issues published annually: 12; 6. Annual subscription price: $216.00 7. Complete mailing address of known office of publication: Lippincott Williams & Wilkins, 16522 Hunters Green Parkway, Hagerstown, MD 21740-2116. 8. Complete mailing address of the headquarters of general business offices of the publisher: 530 Walnut Street, Philadelphia, PA 19106. 9. Full names and complete mailing address of publisher, editor, and managing editor: Publisher: Lippincott Williams & Wilkins, Inc., 530 Walnut Street, Philadelphia, PA 19106; Editor: Julius Schachter, PhD, Room 416/Bldg. #30, San Francisco General Hospital, 1001 Potrero Ave., San Francisco, CA 94110: Managing Editor: Jeanne Moncada, Room 416/Bldg. #30, San Francisco General Hospital, 1001 Potrero Ave., San Francisco, CA 94110. 10. Owner: American Sexually Transmitted Diseases Association, c/o: Denver Public Health, 605 Bannock Street, Denver, CO 80204. 11. Known bondholders, mortgagees, and other security holders owning or holding 1% or more of total amount of bonds, mortgages, or other securities: None. 12. Purpose, function, and nonprofit status: Has not changed during preceding 12 months. 13. Publication Name: SEXUALLY TRANSMITTED DISEASES 14. Issue Date for circulation data: Volume 28, Issue 8. 15. Extent and nature of circulation: Average number of copies each issue during preceding 12 months: (a) Total No. copies (Net Press Run), 1,892. (b) Paid and/or requested circulation; (1) Paid/requested outside-county mail subscriptions stated on form 3541. (Include advertiser's proof and exchange copies), 819; (2) Paid in-county subscriptions (include advertiser's proof and exchange copies), N/A; (3) Sales through dealers and carriers, street vendors, counter sales, and other non-USPS paid distribution, 449; (4) Other classes mailed through the USPS, N/A. (c) Total paid and/or requested circulation (sum of 15b (1), (2), (3), and (4), 1,253, (d) Free distribution by mail (samples, complimentary, and other free). (1) Outside-county as stated on form 3541, 70; (2) In country as stated on form 3541, N/A; (3) Other classes mailed through the USPS, N/A. (e) Free distribution outside the mail'(carriers or other means), 45. (f) Total free distribution (sum of 15d and 15e), 115. (g) Total distribution (Sum of 15c and 15f), 1,368. (h) Copies not distributed, 524. (i) Total (sum of 15g and h), 1,892. (j) Percent paid and/or requested circulation (15c divided by 15g times 100), 91.59%. No. copies of single issue published nearest to filing date: (a) Total no. copies (Net Press Run), 1,950. (b) Paid and/or requested circulation; (1) Paid/requested outside-county mail subscriptions stated on form 3541. (Include advertiser's proof and exchange copies), 820; (2) Paid in-county subscriptions (include advertiser's proof and exchange copies), N/A; (3) Sales through dealers and carriers, street vendors, counter sales, and other non-USPS paid distribution, 433; (4) Other classes mailed through the USPS, N/A. (c) Total paid and/or requested circulation (sum of 15b. (1), (2), (3), and (4), 1,253. (d) Free distribution by mail (samples, complimentary, and other free), (1) Outside-county as stated on form 3541, 41; (2) In-county as stated on form 3541, N/A; (3) Other classes mailed through the USPS, N/A. (e) Free distribution outside the mail (carriers or other means), 17. (f) Total free distribution (sum of 15d and 15e), 58. (g) Total distribution (Sum of 15c and 15f), 1,311. (h) Copies not distributed, 639. (i) Total (sum of 15g and h), 1,950. (j) Percent paid and/or requested circulation (15c divided by 15g x 100), 95.58%. 16. This Statement of Ownership will be printed in volume 28, issue 12 of this publication. 17. I certify that the statements made by me above are correct and complete. Jeffrey Brown, Manager, Periodical Operations

INDEX OF SUBJECTS

A

Abortion, early suction, antibiotic prophylaxis for, 714
Adolescents
  chlamydia testing in, in managed care organization, 477
  female, sexual initiation in, predictors of and developmental trends in, 527, 533 (editorial)
  female high-risk, partner choice/behavior and, 247
  female minority
    condom carrying by, condom use and, 444
    gonorrhea in, socioeconomic status and, 236
    validity of self-reported STDs in, 468
  homeless
    chlamydia and gonorrhea in, in Canada, 437
    rates of chlamydia, herpes and hepatitis in, 4
  Kaposi sarcoma–associated HSV infection in, seroprevalence of, in Uganda, 77
  returning for anonymous HIV testing, proportion and characteristics of, 401
  worry about STD vs. HIV infection in, psychosocial correlates of, 108
Africa. *See* Developing countries *and specific countries*
African Americans
  female adolescent
    condom carrying by, condom use and, 444
    gonorrhea in, socioeconomic status and, 236
    validity of self-reported STDs in, 468
  social context of sexual relationships of, 69
Anogenital warts
  in HIV infection, 1% cidofovir cream for, 343
  patient demographics and, 643
  topical imiquimod for, in males, 226
Antibiotic prophylaxis, for early suction abortion, 714
Antimicrobial susceptibility
  of *N gonorrhoeae,* 82
    in Brazil, 521
    to ciprofloxacin, 82
    to ofloxacin, 576
    in Rwanda, 539
    in Trinidad, Guyana and St. Vincent, 508
  of *T vaginalis,* in Spain, 115 (letter)
At-risk populations, home specimen collection and telephone counseling for, 51
Azerbaijan, STDs and reproductive health in, 372
Azithromycin, *N gonorrhoeae* susceptibility to, in Brazil, 521

B

Bacterial vaginosis
  clindamycin phosphate cream vs. triple sulfonamide cream for, 569
  complications of, prevention of, 292
  epidemiologic interactions of with HIV, 579, 613
  Mobiluncus spp and, 195
Book review, 62
Brazil
  herpes simplex virus type 2 infection in, prevalence of and risk factors for, in middle-aged women, 187
N gonorrhoeae antimicrobial sensitivity in, 521
seroprevalence of HIV, hepatitis B and syphilis in, in pregnancy, 710
BufferGel, for contraception and STD prevention, animal models of, 417

C

Cameroon, HSV type 2 in, prevalence and risk factors for, 690
Canada
  chlamydia and gonorrhea in at-risk women, young sex workers and street youth in, 437
  chlamydial infection in
    screening for, cost-effectiveness of swabs vs. urine samples in, 701
    sexual network analysis for, 14
  HSV type 2 antenatal seroprevalence in, 424
  oncogenic HPV infection and cervical lesions in, in aboriginal women, 694
Cancer, cervical
  in Canadian aboriginal women, 694
  HPV infection and, in Mexico City sex workers, 125
Caribbean countries, *N gonorrhoeae* antimicrobial susceptibility in, 508
Case management, in Kenya, 633
Centers for Disease Control and Prevention, STD programs of, managed care organization collaboration in, 336
Cervical cancer
  in Canadian aboriginal women, 694
  HPV infection and, in Mexico City sex workers, 125
Cervical secretions
  Epstein-Barr virus in, 300
  HIV infection shedding in, 347 (letter)
Chancroid, epidemiologic interactions of with HIV, 579, 613
China, knowledge about high-risk sexual practices in, 171
Chlamydial infection
  in at-risk women, young sex workers and street youth, in Canada, 437
  diagnosis of, self-collected vaginal swabs for, 321
  epidemiologic interactions of with HIV, 579, 613
  in family planning clinic attendees, in Turkey, 58
  in Finland, sentinel clinic survey of, 252
  in HIV infection, effects of on HIV shedding in genital tract secretions, 347 (letter)
  in males, in Turkey, 630
  partner management in, 658
  persistent/recurrent, determinants of, 117
  prevalence of, in Czech and Slovak women, 356
  rates of, in homeless adolescents, 4
  rectal, pig-tailed macaque model for, 363
  screening for
    at HIV counseling and testing site, 153
    in incarcerated adolescents, 43
    ligase chain reaction in, 565
    in urban emergency department, 33, 40 (editorial)
    urine-based, in male STD clinic attendees, 219
    urine samples vs. vaginal swabs in, cost-effectiveness of, 701
  sexual network analysis for, in Canada, 14
  testing for, in HMO members presenting with urethritis, 232
Chlamydia trachomatis, identification and persistence of, 684 (Parran Award lecture)
Chronic hepatitis, screening for, at STD clinic, 168
Cidofovir, topical, for anogenital warts, in HIV infection, 343
Ciprofloxacin, *N gonorrhoeae* susceptibility to, 82
  molecular epidemiology of, 309
Circumcision, male
  errors in reported status of, 330
  in Tanzania, 214
  techniques of, in Kenya, 608
Clindamycin phosphate cream, vs. triple sulfonamide cream, for bacterial vaginosis, 569
Cognitive-behavioral skills-building intervention, for STD and HIV prevention, in young military males, 349
Condoms
  female, acceptability of, 655 (editorial)
    to Thai sex workers, 648
  use of
    condom carrying by minority adolescent females and, 444
    determinants of, 552 (editorial)
    self-reported, psychosocial factors in, 387
    by sterilized vs. nonsterilized Hispanic women, 546
Condylomata acuminata
  in HIV infection, 1% cidofovir cream for, 343
  patient demographics and, 643
  topical imiquimod for, in males, 226
Condylomata lata, pedal interdigital, in secondary syphilis, 184
Congenital syphilis
  fluorescent treponemal antibody test reactivity in, after 1 year of age, 412
  in HIV-infected infants, 315
  prevention of, 92

Conjunctivitis, neonatal *N meningitidis*, acquired at delivery from maternal endocervicitis, 29
Contraception. *See also* Condoms
BufferGel for, animal models of, 417
STD prevention and, 522 (editorial)
Core groups
sampling methods and, 200
in sexual network analysis. *See also* Social network analysis
for chlamydia and gonorrhea, in Canada, 14
Czech Republic, prevalence of chlamydia, gonorrhea and HIV infection in, in women, 356

D

Denmark, trichomoniasis epidemiology in, 326
Depression, in STD patients, 281, 285 (editorial)
Developing countries. *See also specific countries*
HIV transmission in, 730 (letter)
enhanced female-to-male, in male core groups, 84
Domestic violence, prevalence of among STD clinic attendees, 143
Douching, pelvic inflammatory disease risk and, 240
Drug abuse. *See* Substance abuse
Duplicate publications, 495, 496

E

Elderly, STD prevalence in, 287
ELISA, glycoprotein G–based, for HSV type 2, 99
Emergency department, urban, as screening site for gonorrhea and chlamydia, 33, 40 (editorial)
Endometritis, risk of, douching and, 240
Epidemiology, of STDs
in homeless adolescents, 4
in transportation workers, 11
Epstein-Barr virus, in cervical secretions, 300
Errata, 307, 429
Estonia, STD prevalence in, sexual behavior and beliefs and, 624

F

Family planning clinic attendees, curable STDs in, in Turkey, 58
Female condoms, acceptability of, 655 (editorial)
to Thai sex workers, 648
Finland, chlamydial infection in, sentinel clinic survey of, 252
Fluorescent treponemal antibody test reactivity, in congenital syphilis, after 1 year of age, 412
Foot, interdigital condylomata lata of, in secondary syphilis, 184

G

Gatifloxacin, single-dose, for gonorrhea, vs. ofloxacin, 136
Gay men
hepatitis C testing for, 515
human herpesvirus 8 in, seroprevalence of and risk factors for, 176
STD and HIV screening guidelines for, 457, 460 (editorial)
Genital herpes. *See* Herpes simplex virus infection
Genital ulcers. *See also specific causes*
in rural Uganda, HIV control and, 431
syphilitic, presentation of, in HIV infection, 448
Genital warts
in HIV infection, 1% cidofovir cream for, 343
patient demographics and, 643
topical imiquimod for, in males, 226
Glycoprotein G–based ELISA, for HSV type 2, 99
Gonorrhea
in at-risk women, young sex workers and street youth, in Canada, 437
ciprofloxacin-resistant, 82
diagnosis of, self-collected vaginal swabs for, 321
epidemiologic interactions of with HIV, 579, 613
in female adolescent African Americans, socioeconomic status and, 236
immunity to reinfection in, 555
in males, in Turkey, 630
partner management in, 658
prevalence of, in Czech and Slovak women, 356
reemergence of, epidemiology of, in Sweden, 111
screening for
in HMO members presenting with urethritis, 232
in urban emergency department, 33, 40 (editorial)
sexual network analysis for, in Canada, 14
single-dose gatifloxacin for, vs. ofloxacin, 136
Guyana, *N gonorrhoeae* antimicrobial susceptibility in, 508

H

Healthcare-seeking behavior, of STD patients, in Kenya, 367
Health maintenance organizations. *See* Managed care organizations
Hepatitis, rates of, in homeless adolescents, 4
Hepatitis B
chronic, screening for, at STD clinic, 168
immunization for
acceptance of, 678
for STD clinic attendees, 148
seroprevalence of, in pregnant Brazilian women, 710
in substance abuse patients, in Jamaica, 266
Hepatitis C
chronic, screening for, at STD clinic, 168
enhanced sexual transmission of, in HIV infection, 725
testing for, in men who have sex with men, 515
Herpes simplex virus infection
Kaposi sarcoma–associated, seroprevalence of, in Ugandan adolescents and young adults, 77
rates of, in homeless adolescents, 4
in rural Uganda, HIV control and, 431
type 2
antenatal seroprevalence of, in Canada, 424
epidemiologic interactions of with HIV, 579, 613
glycoprotein G–based ELISA for, 99
microbicide efficacy against, in mice, 259
in middle-aged Mexican women, 270
prevalence and risk factors for, in Cameroon, 690
seroprevalence and risk factors for, in middle-aged women, in Brazil and the Philippines, 187
seroprevalence and seroconversion of, in Spain, 47
type w, prevention of, thermoreversible gel for, 484
High-risk sexual behavior, among STD clinic attendees, in China, 171
Hispanic women, sterilized vs. nonsterilized, condom use by, 546
HIV infection
abdolescents' worry about, psychosocial correlates of, 108
anonymous testing for, proportion and characteristics of adolescents returning for, 401
chlamydial coinfection in, effects of on HIV shedding in genital tract secretions, 347 (letter)
counseling and testing site for, chlamydia screening at, 153
early-stage syphilis in, clinical manifestations of, 158
enhanced female-to-male transmission of, in male core groups, in developing countries, 84
enhanced sexual transmission of hepatitis C in, 725
epidemiologic interactions of with classic STDs, 579, 613
in foreign transsexual sex workers, in Rome, 405
home specimen collection for, provider vs. client attitudes toward, 51
HSV infection and, in rural Uganda, 431
maternal-infant infection with, congenital syphilis and, 315
prevalence of, in Czech and Slovak women, 356
prevention of
thermoreversible gel for, 484
in young military men, 349
screening for, in men who have sex with men, 457
seroprevalence of, in pregnant Brazilian women, 710
STD clinic preventive services for, 455 (letter), 460
STD cofactors effects in, magnitude of, 613, 621 (editorial)
in substance abuse patients, in Jamaica, 266
syphilitic genital ulcer presentation in, 448
transmission of, in developing countries, 730 (letter)
Homeless adolescents
chlamydia and gonorrhea in, in Canada, 437
rates of chlamydia, herpes and hepatitis in, 4
Home specimen collection, for HIV infection, provider vs. client attitudes toward, 51
Homosexuals, male
hepatitis C testing for, 515

human herpesvirus 8 in, seroprevalence of and risk factors for, 176
STD and HIV screening guidelines for, 457, 460 (editorial)
Human herpesvirus 8, seroprevalence of and risk factors for, among gay men, 176
Human papillomavirus infection
detection of via penile-urethral swabs vs. urine samples in, in Mexican males, 277
genital warts in
in HIV infection, 1% cidofovir cream for, 343
patient demographics and, 643
topical imiquimod for, in males, 226
oncogenic, in aboriginal women in Canada, 694
prevalence of, in Mexico City sex workers, 125
Human T-cell lymphotropic virus infection, in substance abuse patients, in Jamaica, 266

I

Imiquimod, topical, for genital warts, in males, 226
Immunization, for hepatitis B
acceptance of, 678
for STD clinic attendees, 148
Incarcerated/detained persons, adolescent, chlamydia screening in, 43
Interviewing techniques, for partner recall, 666
Italy, foreign transsexual sex workers in, HIV infection in, 405

J

Jamaica, substance abuse patients in, bloodborne STDs in, 266

K

Kaposi sarcoma–associated HSV infection, seroprevalence of, in Ugandan adolescents and young adults, 77
Kenya
case management in, 633
male circumcision technique in, 608
STD patients in, healthcare-seeking and sexual behavior of, 367

L

Ligase chain reaction, in chlamydia screening, 565

M

Managed care organizations
adolescent chlamydia testing in, 477
collaboration of in federally funded STD programs, 336
Men who have sex with men
hepatitis C testing for, 515
human herpesvirus 8 in, seroprevalence of and risk factors for, 176
STD and HIV screening guidelines for, 457, 460 (editorial)
Mexico
herpes simplex virus type 2 infection in, in middle-aged women, 270
HPV infection prevalence among sex workers in, 125
Microbicides, relative efficacy of against HSV-2 infection, in mice, 259
Military personnel, male, prevention of STDs and HIV in, 349
Mobiluncus spp, in women with/without bacterial vaginosis, 195
Motorcycle taxi drivers, STD rates in, in a Peruvian Amazon city, 11
Mycoplasma genitalium, urethral persistence of, recurrent nongonococcal urethritis and, 472

N

Neisseria gonorrhoeae. *See also* Gonorrhea
antimicrobial susceptibility of
in Brazil, 521
to ciprofloxacin, 82 molecular epidemiology of, 309
to ofloxacin, 576
in Rwanda, 539
in Trinidad, Guyana and St. Vincent, 508
Neisseria meningitidis conjunctivitis, neonatal, acquired at delivery from maternal endocervicitis, 29
Network analysis. *See* Social network analysis
5-Nitroimidazole, *T vaginalis* resistance to, in Spain, 115 (letter)
Nongonococcal urethritis, recurrent, urethral persistence of *Mycoplasma genitalis* and, 472
Nonoxynol-9 gel, low-dose, for STD prevention, 394

O

Obituaries, 2, 493
Ofloxacin
for gonorrhea, vs. gatifloxacin, 136
N gonorrhoeae resistance to, 576
Older (50) adults, STDs in, 287
Oriel, John David, 2 (obituary)
Outbreak assessment, for syphilis, 131

P

Partner management
in chlamydia and gonorrhea, 658
patient-delivered medication in, in Uganda, 105
Partner notification, recall for, interviewing techniques for, 666
Patient-delivered partner medication, in Uganda, 105
Pedal interdigital condylomata lata, in secondary syphilis, 184
Pelvic inflammatory disease, risk of, douching and, 240
Penicillin, *N gonorrhoeae* susceptibility to
in Brazil, 521
in Rwanda, 521
Penile-urethral swabs, vs. urine samples, for detection of HPV, in Mexican males, 277
Philippines, HSV type 2 infection in, prevalence of and risk factors for, in middle-aged women, 187
Pig-tailed macaque rectal model, 363
Polymerase chain reaction, in detection of Epstein-Barr virus in cervical secretions, 300
Pregnancy
HSV type 2 seroprevalence of, in Canada, 424
seroprevalence of HIV, hepatitis B and syphilis in, in Brazil, 710
syphilis in
in HIV infected mother, congenital syphilis risk and, 315
prevention of fetal transmission in, 92
Prisoners. *See* Incarcerated/detained persons
Prostitutes. *See* Sex workers
Psychiatric morbidity, in STD patients, 281, 285 (editorial)
Psychosocial factors
in female sexual initiation, 527, 533 (editorial)
in self-reported male condom use, 387

R

Rectal microflora, pig-tailed macaque model of, chlamydial infection and, 363
Rwanda, *N gonorrhoeae* antimicrobial susceptibility in, 539

S

Safe sex practices. *See also* Sexual behavior
in Azerbaijan, 367
in Kenya, 367
of recurrently infected patients, 379
St. Vincent, *N gonorrhoeae* antimicrobial susceptibility in, 508
Screening
for chlamydia
at HIV counseling and testing site, 153
in HMO members presenting with urethritis, 232
in incarcerated adolescents, 43
ligase chain reaction in, 565
in urban emergency department, 33, 40 (editorial)
urine-based screening for, in male STD clinic attendees, 219
urine samples vs. vaginal swabs in, cost-effectiveness of, 701
for chronic hepatitis, at STD clinic, 168
at family-planning clinics, in Turkey, 58
for gonorrhea
in HMO members presenting with urethritis, 232
in urban emergency department, 33, 40 (editorial)
for hepatitis C, in men who have sex with men, 515
for HSV type 2, glycoprotein G–based ELISA for, 99
for STDs and HIV, in men who have sex with men, 457
Semen acidification, by BufferGel, animal models of, 417
Sexual behavior
in Azerbaijan, 367
high-risk, among STD clinic attendees, in China, 171

of high-risk adolescent females, partner choice/behavior and, 247
in Kenya, 367
of recurrently infected patients, 379
of STD patients, in Kenya, 367
STD risk and, in Estonia, 624
substance abuse and, in high-risk young adults, 598
Sexual initiation, female, predictors of and developmental trends in, 527, 533 (editorial)
Sexually transmitted disease clinic attendees
chronic hepatitis screening for, 166
domestic violence prevalence among, 143
hepatitis B immunization for, 148
male, urine-based screening for chlamydia in, 219
repeat, characteristics of, 379
Sexually transmitted disease clinics, preventive services of, for HIV-infected patients, 455 (letter), 460
Sexually transmitted disease programs, federally funded, managed care organization collaboration in, 336
Sexually transmitted diseases
adolescents' worry about, psychosocial correlates of, 108
bloodborne, in substance abuse patients, in Jamaica, 266
curable, among family-planning clinic attendees, in Turkey, 58
depression and, 281, 285 (editorial)
epidemiologic interactions of with HIV, 579, 613, 622 (editorial)
epidemiology of, in older (50) persons, 287
in motorcycle taxi drivers, in a Peruvian Amazon city, 11
prevention of, in young military men, 349
recurrent, patient characteristics in, 379
screening for, in men who have sex with men, 457
sources of care in, 535
Sexual network analysis. *See* Social network analysis
Sexual partners. *See under* Partner
Sex workers
chlamydia and gonorrhea in, in Canada, 437
female condom use by, in Thailand, 648
foreign transsexual, HIV infection in, in Rome, 405
HPV infection prevalence in, in Mexico City, 125
Slovak Republic, prevalence of chlamydia, gonorrhea and HIV infection in, in women, 356
Social context, of sexual relationships, among African Americans, 69
Social network analysis, 63
in areas of persistent syphilis, 497, 504 (editorial)
for chlamydia and gonorrhea, in Manitoba, Canada, 14
development and applications of, 25 (editorial)
partner recall in, interviewing techniques for, 666
sampling methods in, 200
Socioeconomic status, of female adolescent African Americans with gonorrhea, 236
Soldiers, male, prevention of STDs and HIV in, 349
Spain
ofloxacin-resistant *N gonorrhoeae* in, 576
seroprevalence and seroconversion of HSV-2 in, 47
Specimen collection, at-home, for HIV infection, provider vs. client attitudes toward, 51
Spousal abuse, prevalence of among STD clinic attendees, 143
Street youth, chlamydia and gonorrhea in, in Canada, 437
Substance abuse
partner recall for, interviewing techniques for, 666
sexual behavior and, in high-risk young adults, 598
Substance abuse clinic attendees, bloodborne sexually transmitted diseases in, in Jamaica, 266
Swabs
penile-urethral, vs. urine samples, for detection of HPV, in Mexican males, 277
self-collected vaginal, for detection of chlamydia, gonorrhea and trichomoniasis, 321
vaginal, vs. urine samples, in chlamydia screening, cost-effectiveness of, 701
Sweden, epidemiology of reemergent gonorrhea in, 111
Syphilis
congenital
fluorescent treponemal antibody test reactivity in, after 1 year of age, 412
in HIV-infected infants, 315
prevention of, 92
early-stage, clinical manifestations of, gender and HIV status and, 158
epidemiologic interactions of with HIV, 579, 613
focal outbreaks of, assessment of and response to, 131
genital ulcers in, presentation of, in HIV infection, 448
in HIV-infected mothers and infants, congenital syphilis risk and, 315
risk assessment for, sexual network analysis in, 497, 504 (editorial)
secondary, pedal interdigital condyloma lata in, 184
seroprevalence of, in pregnant Brazilian women, 710
in substance abuse patients, in Jamaica, 266

T

Tanzania, male circumcision in, 214
Telephone counseling, with home specimen collection, for HIV infection, provider vs. client attitudes toward, 51
Tetracycline, *N gonorrhoeae* susceptibility to
in Brazil, 521
in Rwanda, 521
Thermoreversible gel, for HIV and HSV prevention, 484
Thiamphenicol, *N gonorrhoeae* susceptibility to, in Rwanda, 521
Transfusion-transmitted virus, sexual transmission of, 298 (letter)
Transportation workers, STD rates in, in a Peruvian Amazon city, 11
Transsexual sex workers, foreign, HIV infection in, in Rome, 405
Trichomonas vaginalis, 5-nitroimidazole-resistant, in Spain, 115 (letter)
Trichomonas vaginalis infection
diagnosis of, self-collected vaginal swabs for, 321
epidemiologic interactions of with HIV, 579, 613
epidemiology of, in Danish women, 326
in family planning clinic attendees, in Turkey, 58
Trimethoprim-sulfamethoxazole, *N gonorrhoeae* susceptibility to, in Rwanda, 521
Trinidad, *N gonorrhoeae* antimicrobial susceptibility in, 508
Turkey
chlamydia and gonorrhea urethritis in, 630
chlamydia infection in family planning clinic attendees in, 58

U

Uganda
genital ulcer disease, in rural population, HIV control and, 431
Kaposi sarcoma–associated HSV infection in, seroprevalence of, in adolescents, 77
Urethritis
gonococcal. *See also* Gonorrhea
immunity to reinfection and, 555
HMO members presenting with, *C trachomatis* and *N gonorrhoeae* testing for, 232
nongonococcal, recurrent, urethral persistence of *Mycoplasma genitalis* and, 472
Urine samples
for HPV infection, in Mexican males, 277
vs. vaginal swabs, in chlamydia screening, cost-effectiveness of, 701

V

Vaginal swabs
self-collected, for detection of chlamydia, gonorrhea and trichomoniasis, 321
vs. urine samples, in chlamydia screening, cost-effectiveness of, 701
Vaginosis, bacterial. *See* Bacterial vaginosis
Viral hepatitis. *See* Hepatitis

W

Wang, San-pin, 493 (obituary)
Warts, genital
in HIV infection, 1% cidofovir cream for, 343
patient demographics and, 643
topical imiquimod for, in males, 226